Peter Shepherd
Peter’s lab focusses on how defects in cell signalling pathways control disease processes in Cancer and Metabolic Disease. This has lead to work looking at how combinations to different cell signalling inhibitors can achieve effects on tumours through combined targeting of tumour cells, immune cells and other components in the tumour microenvironment. This involves both developing new drugs to target signalling from CSF1 and VEGFA as well as using novel combinations of old drugs that target cell signalling pathways. The aim is to provide new treatment options for those who fail the current immune therapies.
Abstracts this author is presenting:
